Medicines from Concept to Consumer: AS 6 Study Notes
Welcome to your complete revision guide for Medicines from Concept to Consumer, part of AS 6: Medicine, Drugs and Clinical Trials. Developing a new drug is an incredible journey. Out of thousands of chemical compounds tested in a lab, only a tiny fraction ever make it into our medicine cabinets. In this guide, we will break down every step of this journey: from discovery in the lab to clinical trials on humans, safety regulations, and post-market monitoring.
Don't worry if this seems like a lot of information at first! We will break the whole process down into clear, manageable steps with helpful memory aids.
---1. Drug Discovery and Preclinical Development
Before any drug can be given to human volunteers, scientists must discover a promising compound and thoroughly test its biological effects and safety in the laboratory.
A. Target Identification and Lead Discovery
Every medicine starts with a biological puzzle:
• Target Identification: Scientists identify a specific biological target involved in a disease, such as a faulty receptor, an enzyme, or a signalling pathway.
• Lead Discovery: Researchers look for a "lead compound"—a molecule that can interact with the target to produce a desired effect. These compounds are found by screening natural sources (like plants or microbes), testing large synthetic chemical libraries, or using rational, computer-aided drug design.
B. Preclinical Testing: In Vitro and In Vivo
Once potential lead compounds are identified, they undergo laboratory testing:
• In Vitro Testing (literally "in glass"): Experiments carried out outside a living organism using cell cultures or isolated enzyme assays. This helps scientists assess the drug's bioactivity, binding affinity, and immediate cytotoxicity (whether it poisons or kills cells).
• In Vivo Testing (literally "in living"): Experiments conducted in living animal models. This testing evaluates how the drug interacts with complex, whole-body physiological systems.
C. Pharmacodynamics and Pharmacokinetics (ADME)
Animal testing helps scientists understand two crucial aspects of drug action:
• Pharmacodynamics: What the drug does to the body (its biological effects, mechanism of action, and receptor binding).
• Pharmacokinetics: What the body does to the drug. This is remembered using the acronym ADME:
• A – Absorption: How the drug enters the bloodstream from the site of administration.
• D – Distribution: How the drug disperses throughout bodily fluids and tissues.
• M – Metabolism: How the body biochemically breaks down the drug (primarily in the liver).
• E – Excretion: How the drug and its metabolites are eliminated from the body (primarily via the kidneys in urine or through the digestive tract in faeces).
D. Toxicology and the Therapeutic Index
Preclinical safety testing determines whether the compound carries dangerous side effects before human trials are approved:
• Mutagenicity: Assessing whether the drug causes genetic mutations or DNA damage.
• Teratogenicity: Assessing whether the drug causes developmental defects or malformations in an embryo or foetus.
• Safe Starting Dose: Calculating safe dosage ranges for the very first human studies.
• Therapeutic Index (TI): A quantitative comparison of the drug's safety margin, calculated as:
\(TI = \frac{\text{Toxic Dose}}{\text{Effective Dose}}\)
A higher Therapeutic Index means the drug has a wider safety margin between the dose that cures and the dose that causes harmful toxic effects.
Key Takeaway: Preclinical Stage
Preclinical research uses in vitro (cell/enzyme assays) and in vivo (animal models) studies to evaluate ADME, toxicity (mutagenicity, teratogenicity), and the Therapeutic Index before any human receives a single dose.
---2. The Clinical Trial Phases (Human Testing)
If a drug passes preclinical safety hurdles, it enters human clinical trials. All clinical trials must strictly follow international Good Clinical Practice (GCP) guidelines to ensure patient safety and data integrity.
Phase I: Safety and Screening
• Cohort: A small group of healthy human volunteers (typically \(20\text{–}80\) participants). (Note: In specialized cases such as advanced cancer therapies, patient volunteers may be used instead).
• Primary Aim: Assess overall safety and tolerability, establish safe human dosage ranges, identify immediate side effects, and map human pharmacokinetic (ADME) pathways.
• Why healthy volunteers? To observe baseline drug metabolism without the confounding effects of an existing illness or other medications.
Phase II: Efficacy and Dose-Ranging
• Cohort: A small-to-medium group of patient volunteers suffering from the target disease (typically \(100\text{–}300\) patients).
• Primary Aim: Assess therapeutic efficacy (does the drug actually work to treat the disease?), establish the optimal therapeutic dose regimen, and continue monitoring for short-term side effects.
Phase III: Confirmation and Large-Scale Safety
• Cohort: A large, multi-centre cohort of patients with the target condition (typically \(1,000\text{–}3,000+\) patients across diverse hospitals and regions).
• Primary Aim: Confirm efficacy by comparing the drug against current standard-of-care treatments or placebos, monitor adverse effects across broader and more diverse demographics, and gather statistically robust data required for marketing authorization (licensing).
Phase IV: Post-Marketing Surveillance (Pharmacovigilance)
• Cohort: The general patient population taking the prescribed, marketed drug in real-world settings.
• Primary Aim: Ongoing, long-term monitoring to detect rare or delayed adverse drug reactions (ADRs), assess real-world cost-effectiveness, and evaluate any off-label uses.
Memory Aid: The 4 Phases of Clinical Trials
• Phase I: Is it safe? (Healthy volunteers)
• Phase II: Does it work? (Small patient group, Dose-finding)
• Phase III: Compare and Confirm (Large patient group, licensing)
• Phase IV: Post-marketing Pharmacovigilance (Public population)
Key Takeaway: Clinical Phases
Phase I tests safety in healthy volunteers; Phase II tests efficacy and dosing in a small patient group; Phase III confirms efficacy and safety in thousands of patients against current treatments; Phase IV monitors long-term safety in the wider public after licensing.
---3. Trial Design, Methodology, and Bias Minimisation
To produce reliable scientific evidence, trials must be designed so that results reflect the true action of the drug, rather than researcher expectations or chance differences between groups.
A. Randomisation
Participants are allocated to different study arms (e.g., experimental treatment group vs. control group) purely by chance (using computer algorithms).
• Why it matters: It eliminates selection bias and ensures that baseline patient characteristics (such as age, gender, and disease severity) are balanced evenly across both groups.
B. Control Groups
A control group provides a baseline comparison so researchers can see what would happen without the experimental treatment:
• Placebo Control: An inert, inactive substance (like a sugar pill or saline injection) formulated to look, smell, and taste identical to the experimental drug. Used when no standard treatment currently exists.
• Active Comparator: An existing, approved standard-of-care drug used as the control. The new drug must demonstrate superiority or non-inferiority to this existing medicine.
• Important Ethical Rule: If an effective standard treatment already exists, using a placebo is generally considered unethical because it denies ill patients necessary medical care.
C. Blinding Protocols
Blinding prevents psychological expectations from skewing the results:
• Single-Blind: The participant does not know whether they are receiving the experimental drug or the control, but the doctor/researcher does know. This eliminates the participant's psychological expectation (placebo effect).
• Double-Blind: Neither the participant nor the administering doctor/researcher knows who is receiving the active drug and who is receiving the control. Group codes are held securely until the trial ends.
• Why Double-Blind is the Gold Standard: It eliminates both participant placebo effects and observer/expectancy bias from clinicians assessing symptoms.
D. Inclusion and Exclusion Criteria
These are predefined eligibility rules established before recruiting volunteers:
• Inclusion Criteria: Specific factors required to join (e.g., confirmed clinical diagnosis of the target disease, a specific age range such as \(18\text{–}65\)).
• Exclusion Criteria: Factors that disqualify a person from participating (e.g., pregnancy, severe kidney or liver impairment, or taking conflicting medications that could cause dangerous interactions).
• Purpose: Creates a well-defined, reproducible, and safe patient cohort.
Key Takeaway: Trial Design
Randomisation prevents selection bias, double-blinding prevents observer and placebo bias, and inclusion/exclusion criteria ensure a safe, clearly defined study population.
---4. Ethics, Governance, and UK Regulation
Patient safety and human rights are protected by strict legal and ethical frameworks.
A. Informed Consent
Before any participant enters a trial, they must give written Informed Consent. This requires that:
• Participants receive full, clear explanations of the trial’s purpose, all procedures, potential risks, and known adverse effects in plain language.
• Participants are informed of alternative standard treatments available.
• Participants are explicitly told they have the unconditional right to withdraw from the trial at any point without giving a reason and without any negative impact on their standard medical care.
• Consent is given freely without coercion or financial pressure.
B. Research Ethics Committees (RECs)
An independent body of medical professionals and laypeople that reviews trial proposals before any testing begins.
• Role: They evaluate trial protocols to ensure patient safety safeguards are in place, the risk–benefit ratio is ethically acceptable, and consent procedures are fair and transparent. A trial cannot proceed without REC approval.
C. The MHRA and UK Regulation
The Medicines and Healthcare products Regulatory Agency (MHRA) is the executive agency responsible for regulating medicines and medical devices in the UK:
• Clinical Trial Authorisation (CTA): Grants permission for clinical trials to take place in the UK.
• Marketing Authorisation: Grants the official product licence required before a drug can be manufactured, sold, or prescribed to the public.
• The Yellow Card Scheme: A national UK reporting system operated by the MHRA. It allows healthcare professionals, patients, and carers to report suspected adverse drug reactions (ADRs) for post-market surveillance (Phase IV), helping to detect rare or previously unnoticed side effects.
Key Takeaway: Regulation & Ethics
Informed consent protects patient autonomy; Research Ethics Committees (RECs) approve trial safety; the MHRA licenses medicines in the UK and monitors post-market safety via the Yellow Card Scheme.
---5. Common Exam Pitfalls to Avoid
• Pitfall 1: Mixing up Phase I and Phase II volunteers. Remember: Phase I uses a small group of healthy volunteers to test safety; Phase II is the first phase to test therapeutic efficacy in patients suffering from the disease.
• Pitfall 2: Believing placebos are used in every trial. If an effective standard treatment already exists for a condition, giving a placebo is unethical. In these cases, an active comparator must be used.
• Pitfall 3: Confusing Single-Blind and Double-Blind. In single-blind, only the patient is unaware; in double-blind, both the patient and the administering/assessing clinician are unaware of the treatment allocation.
• Pitfall 4: Mixing up Preclinical and Clinical stages. Preclinical involves cell cultures (in vitro) and animal models (in vivo). Clinical trials always involve human participants.
6. Quick Summary Checklist
Make sure you can confidently explain each step of the journey:
• Lead Discovery: Identifying biological targets and screening candidate molecules.
• Preclinical: In vitro cell assays and in vivo animal models to assess ADME, mutagenicity, teratogenicity, and the Therapeutic Index (\(TI = \frac{\text{Toxic Dose}}{\text{Effective Dose}}\)).
• Phase I: \(20\text{–}80\) healthy volunteers (Safety, dose range, ADME).
• Phase II: \(100\text{–}300\) patient volunteers (Efficacy, dose optimisation, short-term side effects).
• Phase III: \(1,000\text{–}3,000+\) patient volunteers (Comparison with current care, large-scale safety, licensing data).
• Phase IV: Marketed population (Long-term pharmacovigilance, rare ADRs via the MHRA Yellow Card Scheme).
• Trial Quality: Randomisation, double-blinding, placebo/active controls, and strict inclusion/exclusion criteria.
• Governance: Informed consent, REC ethical approval, and MHRA licensing.